William C. Shakespeare
2022
In 2022, William C. Shakespeare earned a total compensation of $2M as Co-Founder, President of Research and Development at Theseus Pharmaceuticals, a 17% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $186,000 |
|---|---|
| Option Awards | $1,380,420 |
| Salary | $465,000 |
| Other | $15,685 |
| Total | $2,047,105 |
Shakespeare received $1.4M in option awards, accounting for 67% of the total pay in 2022.
Shakespeare also received $186K in non-equity incentive plan, $465K in salary and $15.7K in other compensation.
Rankings
In 2022, William C. Shakespeare's compensation ranked 1,710th out of 5,625 executives tracked by ExecPay. In other words, Shakespeare earned more than 69.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,710 out of 5,625 | 70th |
Division Manufacturing | 892 out of 3,053 | 71st |
Major group Chemicals And Allied Products | 359 out of 1,380 | 74th |
Industry group Drugs | 327 out of 1,281 | 75th |
Industry Pharmaceutical Preparations | 234 out of 927 | 75th |
Source: SEC filing on April 26, 2023.
Shakespeare's colleagues
We found two more compensation records of executives who worked with William C. Shakespeare at Theseus Pharmaceuticals in 2022.